Education
About Us
Working with TipRanks
Follow Us
N4 Pharma (GB:N4P)
:N4P
Total Valuation
N4 Pharma has a market cap or net worth of £8.76M. The enterprise value is 435.23K.
Market Cap£8.76M
Enterprise Value435.23K
Share Statistics
N4 Pharma has 832,280,330 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding832,280,330
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
N4 Pharma’s return on equity (ROE) is -1.64 and return on invested capital (ROIC) is -171.94%.
Return on Equity (ROE)-1.64
Return on Assets (ROA)-1.37
Return on Invested Capital (ROIC)-171.94%
Return on Capital Employed (ROCE)-1.87
Revenue Per Employee1.46K
Profits Per Employee-224.00K
Employee Count5
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of N4 Pharma is ―. N4 Pharma’s PEG ratio is 0.04.
PE Ratio―
PS Ratio245.40
PB Ratio2.76
Price to Fair Value2.76
Price to FCF-1.84
Price to Operating Cash Flow-4.31
PEG Ratio0.04
Income Statement
In the last 12 months, N4 Pharma had revenue of 7.28K and earned -1.06M in profits. Earnings per share was 0.00.
Revenue7.28K
Gross Profit7.28K
Operating Income-1.22M
Pretax Income-1.22M
Net Income-1.06M
EBITDA-1.22M
Earnings Per Share (EPS)0.00
Cash Flow
In the last 12 months, operating cash flow was -444.37K and capital expenditures -3.00, giving a free cash flow of -444.37K billion.
Operating Cash Flow-444.37K
Free Cash Flow-444.37K
Free Cash Flow per Share>-0.01
Dividends & Yields
N4 Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.82
52-Week Price Change-3.33%
50-Day Moving Average0.62
200-Day Moving Average0.50
Relative Strength Index (RSI)35.30
Average Volume (3m)672.48K
Important Dates
N4 Pharma upcoming earnings date is Feb 25, 2026, TBA (Confirmed).
Last Earnings DateSep 25, 2025
Next Earnings DateFeb 25, 2026
Ex-Dividend Date―
Financial Position
N4 Pharma as a current ratio of 6.24, with Debt / Equity ratio of 0.00%
Current Ratio6.24
Quick Ratio6.24
Debt to Market Cap0.00
Net Debt to EBITDA0.51
Interest Coverage Ratio0.00
Taxes
In the past 12 months, N4 Pharma has paid -101.00K in taxes.
Income Tax-101.00K
Effective Tax Rate0.08
Enterprise Valuation
N4 Pharma EV to EBITDA ratio is -0.95, with an EV/FCF ratio of -1.20.
EV to Sales159.44
EV to EBITDA-0.95
EV to Free Cash Flow-1.20
EV to Operating Cash Flow-1.20
Balance Sheet
N4 Pharma has £1.73M in cash and marketable securities with £0.00 in debt, giving a net cash position of £1.73M billion.
Cash & Marketable Securities£1.73M
Total Debt£0.00
Net Cash£1.73M
Net Cash Per Share<£0.01
Tangible Book Value Per Share<£0.01
Margins
Gross margin is 47.78%, with operating margin of -16767.37%, and net profit margin of -14542.71%.
Gross Margin47.78%
Operating Margin-16767.37%
Pretax Margin-16767.37%
Net Profit Margin-14542.71%
EBITDA Margin-16767.37%
EBIT Margin-16767.37%
Analyst Forecast
The average price target for N4 Pharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―